Pharma Companies May Get Time Till December To Comply With Schedule M Norms

New Delhi:  The government is likely to give an extension till December this year to the drug manufacturers to implement revised Schedule M, people aware of the matter told ET.

The drug rules will subsequently be amended to provide the extension of time, they said. Once the final notification is published-which is expected this week-the manufacturers will be asked to fill an application with ten drug regulatory authorities detailing the strategy on how they will comply within the prescribed timeline.

As per ET, the health ministry had sought the legal affairs department’s view on its final draft notification on allowing small pharmaceutical companies more time for upgrading their facilities to comply with the revised Schedule M.

Schedule M of the Drugs and Cosmetics Act outlines quality standards for pharmaceutical products. The revised Scheduled M standards  were notified in January last year. While units with annual turnover of more than Rs 250 crore had to comply from July 1, 2023, the implementation date for MSMEs was January 1 this year. However, the MSMEs had sought more time to make the necessary changes in their manufacturing processes. The ministry then issued a draft notification proposing to extend the deadline for the MSMEs. In this regard, it had invited public comments by January 11. “The feedback was compiled and the final draft has been sent to the legal affairs department for vetting,” one of the people cited earlier told ET. The country’s pharma lobby groups have been seeking a two-year extension to the deadline, saying that much time is needed for improving infrastructure, increasing manpower and training.

SOURCE : Economic Times

  • Related Posts

    ‘Did patients come dancing?’ – Rajasthan minister’s remarks about kidney failure case spark row

    On Thursday, Congress workers held protests against the “degrading medical conditions of Rajasthan” and attempted to enter the hospital premises. Rajasthan Health Minister Gajendra Singh Khinvsar’s remarks about women diagnosed…

    Price cap on 2 key cancer drugs increased by 50%

    NEW DELHI: Amid concerns over shortages of two critical cancer medicines, National Pharmaceutical Pricing Authority has approved a 50% hike in ceiling prices of Carboplatin and Cisplatin injections, citing escalating…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    ‘Did patients come dancing?’ – Rajasthan minister’s remarks about kidney failure case spark row

    ‘Did patients come dancing?’ – Rajasthan minister’s remarks about kidney failure case spark row

    Price cap on 2 key cancer drugs increased by 50%

    Price cap on 2 key cancer drugs increased by 50%

    Hospitals can’t force patients to buy medicines from their pharmacies: Maha FDA

    Hospitals can’t force patients to buy medicines from their pharmacies: Maha FDA

    IIT Bhubaneswar researchers develop portable device for accurate arsenic detection

    IIT Bhubaneswar researchers develop portable device for accurate arsenic detection

    Bribe of Rs 3 crore: Delhi Police inspector held, senior public servant under CBI scanner

    Bribe of Rs 3 crore: Delhi Police inspector held, senior public servant under CBI scanner

    No raids till further orders: Maharashtra tells Bombay HC in Patanjali labelling case

    No raids till further orders: Maharashtra tells Bombay HC in Patanjali labelling case